Patient characteristics
| . | Patients n (%) . |
|---|---|
| Total number of patients | 15 |
| sex, n (%), male/female | 9 (60)/6 (40) |
| Age at study enrollment, median (range) y | 54 (21-70) |
| Diagnosis, n (%) | |
| AML | 9 (60) |
| ALL | 1 (6.5) |
| MDS/MPN | 4 (27) |
| Multiple myeloma | 1 (6.5) |
| Donor gender, n (%) | |
| M → M and F → F | 10 (67) |
| F → M | 2 (13) |
| M → F | 3 (20) |
| Donor relationship, n (%) | |
| Matched related | 6 (40) |
| Matched unrelated | 7 (47) |
| Mismatched unrelated (9/10) | 2 (13) |
| Conditioning regime, n (%), myeloablative/reduced intensity | 11 (73)/4 (27) |
| GVHD prophylaxis, n (%) | |
| CSA/MTX with ATG | 5 (33) |
| CSA/MMF with ATG | 10 (67) |
| EBV serostatus, n (%), R1D1/R1D0 | 13 (87)/2 (13) |
| Full donor cell chimerism at the time of enrollment, n (%) | 15 (100) |
| Disease status at enrollment, n (%), first remission/second remission | 13 (87)/2 (13) |
| GVHD history before B-cell transfer, n (%) | |
| No GVHD | 3 (20) |
| Acute GVHD grade 1-2 without subsequent cGVHD | 5 (33) |
| Mild cGVHD with previous aGVHD | 5 (33) |
| Mild de novo cGVHD | 2 (13) |
| Time from allo-HCT to B-cell transfer, median (range), d | 148 (130-160) |
| Number of CD3+ T cells at the time of enrollment, median (range)/μL | 855 (152-4756) |
| Dose level (CD20+cell per body weight), n (%) | |
| 1: 0.5 × 106/kg b.w. | 3 (20) |
| 2: 1.0 × 106/kg b.w. | 3 (20) |
| 3: 2.0 × 106/kg b.w. | 6 (40) |
| 4: 3.0 ×106/kg to 4.0 ×106/kg b.w. | 3 (20) |
| . | Patients n (%) . |
|---|---|
| Total number of patients | 15 |
| sex, n (%), male/female | 9 (60)/6 (40) |
| Age at study enrollment, median (range) y | 54 (21-70) |
| Diagnosis, n (%) | |
| AML | 9 (60) |
| ALL | 1 (6.5) |
| MDS/MPN | 4 (27) |
| Multiple myeloma | 1 (6.5) |
| Donor gender, n (%) | |
| M → M and F → F | 10 (67) |
| F → M | 2 (13) |
| M → F | 3 (20) |
| Donor relationship, n (%) | |
| Matched related | 6 (40) |
| Matched unrelated | 7 (47) |
| Mismatched unrelated (9/10) | 2 (13) |
| Conditioning regime, n (%), myeloablative/reduced intensity | 11 (73)/4 (27) |
| GVHD prophylaxis, n (%) | |
| CSA/MTX with ATG | 5 (33) |
| CSA/MMF with ATG | 10 (67) |
| EBV serostatus, n (%), R1D1/R1D0 | 13 (87)/2 (13) |
| Full donor cell chimerism at the time of enrollment, n (%) | 15 (100) |
| Disease status at enrollment, n (%), first remission/second remission | 13 (87)/2 (13) |
| GVHD history before B-cell transfer, n (%) | |
| No GVHD | 3 (20) |
| Acute GVHD grade 1-2 without subsequent cGVHD | 5 (33) |
| Mild cGVHD with previous aGVHD | 5 (33) |
| Mild de novo cGVHD | 2 (13) |
| Time from allo-HCT to B-cell transfer, median (range), d | 148 (130-160) |
| Number of CD3+ T cells at the time of enrollment, median (range)/μL | 855 (152-4756) |
| Dose level (CD20+cell per body weight), n (%) | |
| 1: 0.5 × 106/kg b.w. | 3 (20) |
| 2: 1.0 × 106/kg b.w. | 3 (20) |
| 3: 2.0 × 106/kg b.w. | 6 (40) |
| 4: 3.0 ×106/kg to 4.0 ×106/kg b.w. | 3 (20) |
aGVHD, acute GVHD; CSA, cyclosporine A; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; MPN, myeloproliferative neoplasm; MTX, methotrexate.